Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

The partnership with Sanofi, which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases, includes three preclinical candidates with potential milestone payments exceeding ...

On Monday, IGM Biosciences, Inc., a pharmaceutical company based in Mountain View, California, announced the termination of a significant collaboration and license agreement with Genzyme Corporation, ...